1. Home
  2. VYX vs PVLA Comparison

VYX vs PVLA Comparison

Compare VYX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$6.96

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$121.50

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYX
PVLA
Founded
1881
2015
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VYX
PVLA
Price
$6.96
$121.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
16
Target Price
$14.64
$161.13
AVG Volume (30 Days)
2.2M
322.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.46
$18.23
52 Week High
$14.67
$151.18

Technical Indicators

Market Signals
Indicator
VYX
PVLA
Relative Strength Index (RSI) 33.87 52.13
Support Level N/A $85.53
Resistance Level $11.17 $147.47
Average True Range (ATR) 0.44 9.83
MACD -0.07 -1.98
Stochastic Oscillator 19.05 10.60

Price Performance

Historical Comparison
VYX
PVLA

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Share on Social Networks: